YTHDF1 and neoplasm: Compared with untreated Ythdf1−/− mice or anti-PD-L1-treated WT mice, Ythdf1−/−- mice treated with PD-L1 checkpoint blockade immunotherapy have been found to show more complete tumor regression, thus suggesting YTHDF1 as a potential target in anti-tumor immunotherapy.